|
|
|
|
Acromegaly Medical and Health News Headlines
|
|
|
|
|
|
|
All Recent Acromegaly Medical Condition News Headlines |
|
|
|
|
ENDO: New Acromegaly Drugs Show Promise (CME/CE)
WASHINGTON (MedPage Today) -- Two investigational therapies for acromegaly achieved substantial reductions in growth hormone and insulin-like growth factor-1 with no safety issues in studies reported here. (Source: MedPage Today Endocrinology)...
POSTED 06/19/2009 at 11:17 AM --
|
[Acromegaly in the elderly.]
CONCLUSION: In the limits of the use of register, these data reveal a high prevalence of diabetes and hypertension in the eldest acromegalic patients. Despite much less frequent surgical intervention, patients' disease under control is equivalent to the younger population 1year after the initial interview, confirming the effectiveness of the choices of treatment.
PMID: 19539897 [PubMed - as supplied by publisher] (Source: Annales d'Endocrinologie)...
POSTED 06/16/2009 at 06:00 PM --
|
Lanreotide for the treatment of acromegaly.
Authors: Castinetti F, Saveanu A, Morange I, Brue T
Lanreotide is an eight-amino acid peptide, which is an analog of the native somatostatin peptide, physiological inhibitor of growth hormone (GH). The drug shows high binding affinity for somatostatin receptors, SSTR2 and SSTR5, which is the primary mechanism considered to be responsible for decreasing GH secretion and GH cell proliferation in acromegaly. Two different formulations of lanreotide are currently available: lanreotide slow release, which requires intramuscular injection every 7-14 days, and lanreotide autogel, which requires deep subcutaneous injection every 4-8 weeks. Several studies have been published to date on the use of lanreotide in acromegaly. Antisecretory efficacy has been reported in 35%-70% of cases; this huge ......
POSTED 06/15/2009 at 06:00 PM --
|
Lanreotide Confers Multiple Benefits In Acromegaly Patients
WASHINGTON D.C. - Most patients with acromegaly who are switched to the long-acting somatostatin analogue lanreotide (SomatulineR Depot) injection from initial treatment with octreotide cite a preference for lanreotide as their future therapy, according to data released here at the 91st Annual Meeting of the Endocrine Society (ENDO 09). (Source: Health News from Medical News Today)...
POSTED 06/13/2009 at 02:00 AM --
|
The physiology of growth hormone and sport.
Authors: Widdowson WM, Healy ML, Sönksen PH, Gibney J
The growth hormone (GH)/ insulin-like growth factor-I (IGF-I) axis exerts short-and long-term metabolic effects that are potentially important during exercise. Exercise is a potent stimulus to GH release and there is some evidence that the acute increase in GH is important in regulating substrate metabolism post-exercise. Regular exercise also increases 24-hour GH secretion rates, which potentially contributes to the physiologic changes induced by training. The effects of GH replacement in GH-deficient adults provide a useful model with which to study the effects of the more long-term effects of the GH/ IGF-I axis. There is convincing evidence that GH replacement increases exercise capacity. Measures of exercise performance inc......
POSTED 06/05/2009 at 06:00 PM --
|
D3 growth hormone receptor polymorphism is not associated with IGF-1 levels in untreated acromegaly.
Conclusions: The exon-3 GHR genotype does not affect the GH/IGF-1 relationship in untreated acromegalic patients with high circulating GH and IGF-1 levels.
PMID: 19439509 [PubMed - as supplied by publisher] (Source: European Journal of Endocrinology)...
POSTED 05/31/2009 at 06:00 PM --
|
Pituitary tumors
Opinion statement Pituitary adenomas are the most common intrasellar tumors. With the exception of prolactinomas, first-line treatment is almost
always surgical. Prolactinomas are usually treated with dopamine agonists such as cabergoline or bromocriptine. Somatostatin
analogues, such as octreotide and lanreotide, can be adjunctive to surgical therapy in acromegaly, although they can be used
as primary therapy in selected cases. Pegvisomant, a growth hormone receptor antagonist, is reserved for acromegalic patients
who are resistant to treatment with somatostatin analogues. No effective medical therapy is available for adenomas that secrete
adrenocorticotropic hormone, and occasionally bilateral adrenalectomy is required to resolve severe hypercortisolemia. Radiation
thera......
POSTED 05/30/2009 at 03:10 AM --
|
Neurofibromatosis With Precocious Puberty and Gigantism
S.J. is a 10-year-old Caucasian boy with a history of precocious puberty. He has been followed in the endocrine clinic for 2 years. S.J. has a significant past history of neurofibromatosis Type 1 (NF1) and presented with signs and symptoms of early puberty manifesting as rapid linear growth, height above the 97% for age, and deepening of his voice, which had been noted by his primary care physician. (Source: Journal of Pediatric Nursing)...
POSTED 05/26/2009 at 09:57 PM --
|
[Anaesthesia for endocrine tumor removal.]
Authors: Billard V, Cheikh M, Delaporte-Cerceau S, Raffin-Sanson ML
Endocrine tumors could be defined by their ability to produce structural proteins or hormones commons to nervous and endocrine cells. They might induce physiological transforms or outcome adverse events which should be well known in order to prevent or treat them early. The goal of this review was to describe these changes, to describe preoperative assessment, and to discuss intraoperative monitoring and drugs choice based on the literature from the last 30 years. As an example, it should be noticed that: (1) preoperative blood pressure control is essential to prepare phaeochromocytoma for surgery. It should be followed during anaesthesia by intensive fluid load, reversible anaesthetic drugs and rational cardiovascular......
POSTED 05/18/2009 at 06:00 PM --
|
Impact of Disease Duration on Coronary Calcification in Patients with Acromegaly
Exp Clin Endocrinol DiabetesDOI: 10.1055/s-0029-1214386AbstractIt is well established, that the increased mortality in patients with acromegaly is due to cardiac diseases. Cardiomyopathy is the predominant cardiac alteration in patients with acromegaly. There are less data about coronary heart disease or coronary calcifications. Electron beam computed tomography (EBCT) is the standard imaging modality for identification of coronary artery calcifications (CAC) and can determine the extent and severity of coronary atherosclerosis. Coronary risk was evaluated by the Framingham risk score (FRS). The prospective study included 30 patients with acromegaly (mean age 53±14 year; 16 females, 14 males; BMI 28.1±3.6 kg/m; mean±SD), 12 patients had active disease (IGF-1 751±338 &......
POSTED 05/15/2009 at 03:15 AM --
|
Boehringer Ingelheim and DeveloGen AG announce agreement in the field of diabetes, obesity and the metabolic syndrome
Goettingen and Ingelheim/Germany, 13 May 2009 - Boehringer Ingelheim and DeveloGen AG, today announced the signing of an asset sale and purchase and collaboration agreement in the field of diabetes, obesity, the metabolic syndrome and other insulin resistance associated disorders.
Under the terms of the agreement, DeveloGen will receive an upfront payment of € 7 million, but has the opportunity to earn additional deferred payments such as potential milestone payments of up to €237 million as well as tiered sales performance payments. The milestone payments will be due upon achievement of certain preclinical and clinical as well as regulatory and commercial events. Further milestone payments may be achieved with additional compounds and/or additional approved indications. DeveloGen wil......
POSTED 05/12/2009 at 07:00 PM --
|
Technique for surgical tongue reduction in Beckwith-Weidemann syndrome macroglossia
Background and Objectives: Beckwith Weidemann syndrome (BWS) is a rare congenital overgrowth disorder encountered by craniomaxillofacial surgeons. It is characterised by macroglossia, anterior abdominal wall defects, and gigantism. Many techniques have been described to surgically treat the macroglossia associated with this syndrome. The many techniques advocated demonstrate that a less than ideal result is achieved. Our stellate/keyhole surgical reduction pattern allows for the appropriate reduction of tongue mass and volume with conservation of motor and sensory function as well as preservation of good anatomical contour. (Source: International Journal of Oral and Maxillofacial Surgery)...
POSTED 04/30/2009 at 11:00 PM --
|
Successful use of weekly pegvisomant administration in patients with acromegaly.
Conclusions Twice and once-weekly administration of pegvisomant is effective in controlling serum IGF-I levels in acromegaly and although not formally assessed, continuation of weekly dosing in 5 patients at study conclusion suggests patient preference for this regimen.
PMID: 19411301 [PubMed - as supplied by publisher] (Source: European Journal of Endocrinology)...
POSTED 04/30/2009 at 06:00 PM --
|
New Funding for Clinical Endocrine Audit available from the Clinical Endocrinology Trust
The Clinical Endocrinology Trust (a charity which derives its income from a profit-share of the Society’s official clinical journal, Clinical Endocrinology) has long supported Endocrine Audit projects within the UK. Recent examples include the UK Acromegaly Database and the CaHASE audit of adults with CAH. The CET has recently awarded funding to the BTA to evaluate the iodine status of teenage girls across the UK.
The Trustees now invite further Clinical Endocrine Audit applications from Societies or Endocrine Centres. Preference will be given to projects involving multicentre collaborations. We are particularly interested in receiving applications related to areas of endocrinology the Trust has not supported previously. A sum of £40,000 is available during 2009-2010 for one o......
POSTED 04/20/2009 at 07:00 AM --
|
Stereotactic radiosurgery for pituitary adenomas: a comprehensive review of indications, techniques and long-term results using the Gamma Knife
Conclusions Although the effectiveness of radiosurgery varies considerably depending on the adenoma histopathology, volume, and radiation
dose, most studies indicate that radiosurgery when combined with microsurgery is effective in controlling pituitary adenoma
growth and hormone hypersecretion. Long-term follow-up is essential to determine the rate of endocrinopathy, visual dysfunction,
hormonal recurrence, and adenoma volume control.
Content Type Journal ArticleCategory Topic ReviewDOI 10.1007/s11060-009-9832-5Authors
Jay Jagannathan, University of Virginia Health Sciences Center Department of Neurological Surgery Box 800212 Charlottesville VA 22908 USAChun-Po Yen, University of Virginia Health Sciences Center Department of Neurological Surgery Box 800212 Charlottesville VA 22908......
POSTED 04/09/2009 at 02:11 AM --
|
Diastolic Function Study with Conventional and Pulsed Tissue Doppler Echocardiography Imaging in Acromegalic Patients
Acromegaly is associated with myocardial hypertrophy and it can progress to diastolic and systolic dysfunction. Purpose: To evaluate diastolic function in acromegalic patients through conventional echocardiography (CD) and tissue Doppler imaging (TDI). Methods: Seventeen acromegalic patients were submitted to CD and TDI, and early (E) and atriogenic (A) transmitral flow were evaluated in mitral, septal, and tricuspid regions. Results: In comparison with controls the means of conventional (1.06), septal (1.01), and tricuspid (0.98) E/A ratio were significantly lower in acromegalic patients. E/A ratio (Source: Echocardiography)...
POSTED 04/07/2009 at 11:00 PM --
|
Prevalence of growth hormone deficiency (GHD) in cured acromegalic patients: impact of different previous treatments.
Conclusions: severe GHD may occur in about 60% of patients treated for acromegaly, even when cured after S alone. Thus, a stimulation test (i.e. GHRH plus arginine) is recommended in all cured acromegalic patients, independently from previous treatment.
PMID: 19351744 [PubMed - as supplied by publisher] (Source: European Journal of Endocrinology)...
POSTED 04/06/2009 at 06:00 PM --
|
Impairment in Flow-Mediated Vasodilatation of the Brachial Artery in Acromegaly
Med Princ Pract 2009;18:228-232 (DOI:10.1159/000204355) (Source: Medical Principles and Practice : Last 20 articles)...
POSTED 04/06/2009 at 10:24 AM --
|
French consensus on the management of acromegaly.
Authors: Chanson P, Bertherat J, Beckers A, Bihan H, Brue T, Caron P, Chabre O, Cogne M, Cortet-Rudelli C, Delemer B, Dufour H, Gaillard R, Gueydan M, Morange I, Souberbielle JC, Tabarin A,
PMID: 19345931 [PubMed - as supplied by publisher] (Source: Annales d'Endocrinologie)...
POSTED 04/02/2009 at 11:00 PM --
|
Does first-line surgery still have its place in the treatment of acromegaly?
Authors: Castinetti F, Morange I, Dubois N, Albarel F, Conte-Devolx B, Dufour H, Brue T
Transsphenoidal surgery is currently the first-line treatment of acromegaly. Remission is observed in 80 to 90% microadenomas, 50 to 60% non-invasive macroadenomas, and less than 20% invasive macroadenomas. Predictive factors include age, maximal size of the adenoma, cavernous sinus invasion, initial hormone levels and neurosurgeon's experience. Complications are rare, with about 5% definitive diabetes insipidus and 10% of new anterior pituitary hormone deficits. Somatostatin agonist pretreatment can be proposed as it decreases tumor volume in about 25% cases and might reduce the rate of immediate postsurgical complications; however, there is no obvious difference in surgical remission rate whether ......
POSTED 04/01/2009 at 11:00 PM --
|
|
|
|
|
|
 |
|
|
|
|
|
IMPORTANT NOTICE:
The information provided on this site is intended for your general knowledge only and is not a substitute for professional
medical advice or treatment for specific medical conditions. You should not use this information to diagnose or treat a health problem or disease without consulting with a
qualified healthcare provider. Please consult your healthcare provider with any questions or concerns you may have regarding your condition.
|
|
|
|
|
|
|
|
